FDA: Don’t Let GDUFA DMF Assessments Delay ANDAs
This article was originally published in The Gold Sheet
Executive Summary
Generics manufacturers and their active substance suppliers should take steps to protect ANDAs from delays that new user fee requirements could cause, FDA official says. FDA’s new drug master file (DMF) review team will play a key role in keeping the new DMF completeness assessments from delaying ANDA filings.
You may also be interested in...
McKesson Tapped For COVID-19 Vaccine Kits To Meet 1 October Distribution Goal
US HHS turns to COVID-19 vaccine distributor to assemble vaccine administration kits, citing revised vaccine delivery schedule.
Continuous Manufacturing Centers Of Excellence Measure Resurfaces In US House
Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.
COVID-19 Shows US FDA Why It Needs To Know Supply Chain’s Current And Surge Capacities
Agency begins gathering manufacturing plant data to prepare for disruptions that can drain inventories over a weekend.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available Buy Reports
Need a specific report? 1000+ reports available Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: